Table 1 Univariate and multivariate analysis of different prognostic factors for overall survival in patients with LUAD.

From: TMEM9 promotes lung adenocarcinoma progression via activating the MEK/ERK/STAT3 pathway to induce VEGF expression

Characteristics

Total patients(n,%)

Univariate analysis

Multivariate analysis

OS HR (95% CI)

P-value

OS HR (95% CI)

P-value

Gender

     

Male

48 (53.3%)

Reference

   

Female

42 (46.7%)

0.885(0.528–1.484)

0.644

  

Age,year

     

<60

40 (44.4%)

Reference

   

≥60

50 (55.6%)

1.476(0.868–2.510)

0.150

  

T stage

     

T1-2

80 (88.9%)

Reference

   

T3-4

10 (11.1%)

3.473(1.666–7.238)

0.004

3.246 (1.329–7.928)

0.010

N stage

     

Negative

56 (62.2%)

Reference

   

Positive

34 (37.8%)

1.558(0.917–2.645)

0.101

  

Clinical stage

     

I -II

70 (77.8%)

Reference

   

III-IV

20 (22.2%)

2.482 (1.382–4.460)

0.002

1.251 (0.593–2.639)

0.556

Histologic grades

     

1–2

69 (76.7%)

Reference

   

3

21 (23.3%)

2.064(1.164–3.659)

0.013

1.282 (0.673–2.444)

0.450

TMEM9

     

Low

45 (50%)

Reference

   

High

45 (50%)

2.286(1.340–3.901)

0.002

5.925 (3.212–10.929)

0.001

  1. TMEM9, transmembrane protein 9; LUAD lung adenocarcinoma.